Insulet Co. (NASDAQ:PODD) Receives Average Recommendation of “Moderate Buy” from Analysts

Insulet Co. (NASDAQ:PODD) has been given an average recommendation of “Moderate Buy” by the sixteen analysts that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $240.33.

Several brokerages recently weighed in on PODD. Piper Sandler decreased their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. JPMorgan Chase & Co. raised their price objective on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Wolfe Research upgraded shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 target price for the company in a research note on Tuesday. Stifel Nicolaus raised their price target on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Finally, Barclays cut their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th.

Insulet Price Performance

Shares of Insulet stock opened at $184.28 on Wednesday. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86. The firm has a fifty day simple moving average of $170.08 and a 200-day simple moving average of $181.70. The stock has a market capitalization of $12.90 billion, a price-to-earnings ratio of 63.33, a PEG ratio of 3.14 and a beta of 1.00. Insulet has a 1-year low of $125.82 and a 1-year high of $331.65.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. The firm had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business’s revenue was up 37.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.55 EPS. On average, sell-side analysts expect that Insulet will post 3.08 earnings per share for the current year.

Insider Buying and Selling

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.47% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently made changes to their positions in the company. Capital Research Global Investors boosted its position in Insulet by 19.7% in the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after buying an additional 1,556,455 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Insulet by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 8,029,608 shares of the medical instruments supplier’s stock worth $1,742,264,000 after acquiring an additional 29,387 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in shares of Insulet by 18.9% in the 1st quarter. Baillie Gifford & Co. now owns 1,442,279 shares of the medical instruments supplier’s stock worth $247,207,000 after acquiring an additional 229,520 shares in the last quarter. Norges Bank bought a new stake in Insulet during the 4th quarter worth approximately $227,655,000. Finally, Goldman Sachs Group Inc. increased its holdings in Insulet by 56.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock valued at $190,623,000 after purchasing an additional 316,649 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.